MetLife Investment Management LLC Acquires 557 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

MetLife Investment Management LLC boosted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,946 shares of the medical instruments supplier’s stock after purchasing an additional 557 shares during the period. MetLife Investment Management LLC’s holdings in ICU Medical were worth $2,009,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Harvest Fund Management Co. Ltd purchased a new position in ICU Medical in the fourth quarter valued at approximately $33,000. Murphy & Mullick Capital Management Corp purchased a new position in ICU Medical in the fourth quarter valued at approximately $52,000. Venturi Wealth Management LLC lifted its stake in ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 206 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 300 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its stake in ICU Medical by 813.5% in the fourth quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier’s stock valued at $105,000 after purchasing an additional 602 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Up 0.2 %

ICUI stock opened at $135.90 on Tuesday. ICU Medical, Inc. has a twelve month low of $95.44 and a twelve month high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $3.34 billion, a PE ratio of -29.74 and a beta of 0.86. The stock has a 50-day simple moving average of $143.25 and a two-hundred day simple moving average of $157.64.

Wall Street Analysts Forecast Growth

ICUI has been the topic of several research analyst reports. StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Thursday, April 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Tuesday, April 8th. KeyCorp reduced their target price on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Finally, Raymond James set a $97.00 target price on ICU Medical in a report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $162.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.